Danaher (NYSE:DHR) Issues FY 2025 Earnings Guidance

Danaher (NYSE:DHR - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 7.600-7.750 for the period, compared to the consensus estimate of 7.670. The company issued revenue guidance of -.

Danaher Price Performance

Shares of DHR traded up $0.87 during midday trading on Friday, hitting $197.37. The company's stock had a trading volume of 2,608,666 shares, compared to its average volume of 3,354,979. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher has a one year low of $171.00 and a one year high of $281.70. The stock has a market capitalization of $141.06 billion, a price-to-earnings ratio of 37.38, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The company's fifty day simple moving average is $200.87 and its two-hundred day simple moving average is $224.27.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. As a group, equities analysts expect that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 25th. Shareholders of record on Friday, March 28th were given a $0.32 dividend. The ex-dividend date was Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. This is a positive change from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DHR. The Goldman Sachs Group cut their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday. Raymond James restated a "market perform" rating on shares of Danaher in a report on Monday, February 3rd. Wells Fargo & Company dropped their price objective on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Robert W. Baird reduced their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research note on Tuesday, April 22nd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average price target of $264.40.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company's stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.